317 related articles for article (PubMed ID: 19631713)
1. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
2. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
4. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
Sun H; Tsai Y; Nowak I; Liesveld J; Chen Y
Stem Cell Res; 2012 Sep; 9(2):77-86. PubMed ID: 22683680
[TBL] [Abstract][Full Text] [Related]
6. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
7. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Haselboeck J; Kaider A; Pabinger I; Panzer S
Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
[TBL] [Abstract][Full Text] [Related]
8. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.
Di Buduo CA; Currao M; Pecci A; Kaplan DL; Balduini CL; Balduini A
Haematologica; 2016 Dec; 101(12):1479-1488. PubMed ID: 27515246
[TBL] [Abstract][Full Text] [Related]
9. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
11. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
16. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.
Stasi R
Expert Opin Drug Discov; 2009 Jan; 4(1):85-93. PubMed ID: 23480339
[TBL] [Abstract][Full Text] [Related]
18. The biology of thrombopoietin and thrombopoietin receptor agonists.
Kuter DJ
Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin amplifies ADP-induced HSP27 phosphorylation in human platelets: importance of pre-treatment.
Cuong NT; Doi T; Matsushima-Nishiwaki R; Akamatsu S; Kuroyanagi G; Kondo A; Mizutani J; Wada I; Otsuka T; Tokuda H; Kozawa O; Ogura S
Int J Mol Med; 2013 Jun; 31(6):1291-7. PubMed ID: 23588296
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
Xie C; Zhao H; Bao X; Fu H; Lou L
J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
